Episode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro Bio
Between the Biotech Waves
00:00
PKPD
Alpha-1, energy deficiency presents a unique challenge where there are no large animals to test this disease out or the viability of this drug product. We've designed some ways in which we can triangulate between a couple of different cell types. The minute you saw something in monkeys, you had to jump up for joy, and we did the exact same thing at Intellia.
Transcript
Play full episode
